JP2001508424A - 生物学的に活性な物質と、その製造方法と、それを含む組成物 - Google Patents
生物学的に活性な物質と、その製造方法と、それを含む組成物Info
- Publication number
- JP2001508424A JP2001508424A JP52967998A JP52967998A JP2001508424A JP 2001508424 A JP2001508424 A JP 2001508424A JP 52967998 A JP52967998 A JP 52967998A JP 52967998 A JP52967998 A JP 52967998A JP 2001508424 A JP2001508424 A JP 2001508424A
- Authority
- JP
- Japan
- Prior art keywords
- fruit
- biologically active
- synthesis
- active substance
- heat shock
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 229940088623 biologically active substance Drugs 0.000 title claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 title description 6
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims abstract description 60
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims abstract description 60
- 241000196324 Embryophyta Species 0.000 claims abstract description 41
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 31
- 230000004060 metabolic process Effects 0.000 claims abstract description 31
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 31
- 239000000126 substance Substances 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 14
- 235000013399 edible fruits Nutrition 0.000 claims description 49
- 239000000284 extract Substances 0.000 claims description 33
- 240000001439 Opuntia Species 0.000 claims description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 18
- 239000002537 cosmetic Substances 0.000 claims description 11
- 231100000252 nontoxic Toxicity 0.000 claims description 11
- 230000003000 nontoxic effect Effects 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 235000016709 nutrition Nutrition 0.000 claims description 10
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 claims description 8
- -1 aliphatic alcohols Chemical class 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 5
- 239000003495 polar organic solvent Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 238000007738 vacuum evaporation Methods 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 241000219357 Cactaceae Species 0.000 abstract description 17
- 241000220151 Saxifragaceae Species 0.000 abstract description 5
- 239000012620 biological material Substances 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 231100000065 noncytotoxic Toxicity 0.000 abstract 1
- 230000002020 noncytotoxic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 19
- 210000002950 fibroblast Anatomy 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 210000002510 keratinocyte Anatomy 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 14
- 230000009545 invasion Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 101710113864 Heat shock protein 90 Proteins 0.000 description 11
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 11
- 230000035882 stress Effects 0.000 description 11
- 230000035939 shock Effects 0.000 description 10
- 230000014616 translation Effects 0.000 description 9
- 238000001243 protein synthesis Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 230000002438 mitochondrial effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000220284 Crassulaceae Species 0.000 description 2
- 235000004727 Opuntia ficus indica Nutrition 0.000 description 2
- 240000009297 Opuntia ficus-indica Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000036561 sun exposure Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002024 thermoprotective effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101100124795 Caenorhabditis elegans hsp-110 gene Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241001647091 Saxifraga granulata Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004177 carbon cycle Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003382 ingestive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. CAM代謝植物から単離された熱ショックタンパク質(HSP)の合成を 加速および/または増幅する非毒性な生物学的に活性な物質。 2. 植物の果実の皮から得られた請求項1に記載の生物学的に活性な物質。 3. Opuntiaの果実、特にprickly pearの皮から得られた請求項1または2に 記載の生物学的に活性な物質。 4. CAM代謝を有する植物の果実を乾燥し、脱水し、極性有機水で浸出して 有機果実抽出物を得、得られた抽出物を水で希釈し、希釈した抽出物をヘキサン で浸出して精製し、ヘキサン有機留分を分離し、真空蒸発で乾燥してCAM代謝 を有する植物の果実の活性留分を得る請求項1〜3のいずれか一項に記載の生物 学的に活性な物質を得る方法。 5. 極性有機溶媒として脂肪族アルコールおよび脂肪族ケトンから選択した溶 媒を用いる請求項4に記載の生物学的に活性な物質を得る方法。 6. 果実の皮を剥くか、浸食するか、粉砕してCAM代謝植物の果実の皮を得 る請求項4または5に記載の方法。 7. 請求項1〜3のいずれか一項に記載の一つまたは複数の物質を主成分とし て含み、用途に適した非毒性の賦形剤または不活性賦形剤と組み合わされた、必 要に応じて一つまたは複数の補完的な作用を有する成分をさらに含む、熱ショッ クタンパク質(HSP)の合成を加速および増幅する、薬用、美容および/また は栄養組成物。 8. 賦形剤または不活性賦形剤が経消化器、非経口、局所投与または直腸経路 による投与に適している請求項7に記載の薬用、美容および/または栄養組成物 。 9. 主成分の含有量が単位投与量当たり10.10-3mg/ml〜400mg /mlである請求項7または8に記載の薬用、美容および/または栄養組成物。 10. 細胞培養媒体中での熱ショックタンパク質(HSP)の合成を加速また は増幅での請求項1〜3いずれか一項に記載の生物学的に活性な物質の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR96/16116 | 1996-12-27 | ||
FR9616116A FR2757863B1 (fr) | 1996-12-27 | 1996-12-27 | Nouvelles substances a activite biologique, leur procede d'obtention et les compositions en renfermant |
PCT/FR1997/002375 WO1998029128A1 (fr) | 1996-12-27 | 1997-12-22 | Substances a activite biologique, leur procede d'obtention et les compositions en renfermant |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001508424A true JP2001508424A (ja) | 2001-06-26 |
Family
ID=9499223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52967998A Pending JP2001508424A (ja) | 1996-12-27 | 1997-12-22 | 生物学的に活性な物質と、その製造方法と、それを含む組成物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US6737086B2 (ja) |
EP (1) | EP0948340B1 (ja) |
JP (1) | JP2001508424A (ja) |
AP (1) | AP1085A (ja) |
AT (1) | ATE214612T1 (ja) |
AU (1) | AU726744B2 (ja) |
DE (1) | DE69711230T2 (ja) |
DK (1) | DK0948340T3 (ja) |
ES (1) | ES2174328T3 (ja) |
FR (1) | FR2757863B1 (ja) |
PT (1) | PT948340E (ja) |
WO (1) | WO1998029128A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10426723B2 (en) | 2014-12-03 | 2019-10-01 | Mary Kay Inc. | Cosmetic compositions |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2787996B1 (fr) * | 1998-12-30 | 2002-05-10 | Dior Christian Parfums | Composition cosmetique ou dermatologique contenant un actif stimulant la synthese de la proteine hsp 32 dans la peau et methode de traitement cosmetique |
US20040228816A1 (en) * | 1998-12-30 | 2004-11-18 | Carine Nizard | Cosmetic or dermatological composition containing an active agent which stimulates synthesis of the protein HSP 32 in the skin |
FR2792832B1 (fr) * | 1999-04-28 | 2002-05-10 | Codif Internat Sa | Procede de protection de la peau pour la prevenir de son vieillissement cellulaire |
JP2001026546A (ja) * | 1999-07-14 | 2001-01-30 | Fujiharu Tanji | 発がん抑制剤 |
FR2809308B1 (fr) * | 2000-05-29 | 2003-12-26 | Seporga Lab | Preparations cosmetiques ou dermo-pharmaceutiques contenant des hsp et hsf provenant d'un extrait de champignons ou de levures stresses |
FR2810241B1 (fr) * | 2000-06-15 | 2003-10-17 | Seporga Lab | Preparations cosmetiques ou dermo-pharmaceutiques renfermant un extrait de zooplancton qui contient et induit des hsp |
EP1166765A3 (de) * | 2000-06-20 | 2002-05-02 | Laboratoires Serobiologiques | Verfahren zum Schutz der menschlichen Haut |
KR100435855B1 (ko) * | 2001-09-13 | 2004-06-12 | 주식회사 태평양 | 손바닥선인장 추출물을 함유하는 피부 외용제 조성물 |
US7455863B2 (en) * | 2002-11-07 | 2008-11-25 | Smarthealth, Inc. | Flexible elastomer articles and methods of manufacturing |
US7585526B2 (en) | 2002-11-07 | 2009-09-08 | Smarthealth, Inc. | Flexible elastomer articles and methods of manufacturing |
US7776368B2 (en) * | 2003-08-13 | 2010-08-17 | Smarthealth, Inc. | Gloves containing dry powdered aloe and method of manufacturing |
US7399490B2 (en) * | 2004-05-17 | 2008-07-15 | Lean For Life, Inc. | Compositions containing a nopal cactus isolate and method for making same |
FR2877843B1 (fr) * | 2004-11-18 | 2008-09-26 | Biolog Vegetale Yves Rocher Sa | Utilisation de la betaine pour fabriquer une composition cosmetique ou dermatologique |
FR2894828B1 (fr) * | 2005-12-21 | 2008-01-18 | Jean Alexis Grimaud | Nouvelles compositions cosmetologiques et/ou dermatologiques a base de derives de la proline et leurs utilisations |
US7722904B2 (en) * | 2007-11-01 | 2010-05-25 | Access Business Group International Llc | Compositions and methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid |
AT507988B1 (de) | 2009-01-15 | 2012-06-15 | Kaahee Res And Dev Gmbh | Kaktusfruchtextrakt |
US8932571B2 (en) | 2009-03-10 | 2015-01-13 | Alfa Biogene International B.V. | Skin care product |
EP2928485B1 (en) | 2012-12-07 | 2018-04-04 | Alfa Biogene International B.V. | Hsp for use in treatment for imiquimod related side effects |
MY199162A (en) * | 2013-02-26 | 2023-10-18 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
PE20180484A1 (es) | 2015-10-02 | 2018-03-07 | Hoffmann La Roche | Moleculas biespecificas de union a antigeno activadoras de celulas t |
IL257696B2 (en) | 2015-12-09 | 2024-11-01 | Hoffmann La Roche | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
WO2017106284A1 (en) | 2015-12-18 | 2017-06-22 | Mary Kay Inc. | Topical cosmetic compositions |
AU2017205089B2 (en) | 2016-01-08 | 2023-10-05 | F. Hoffmann-La Roche Ag | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
FR3122991B1 (fr) | 2021-05-20 | 2024-05-31 | Patrinove | Extrait de vegetal a metabolisme acide crassulaceen pour utilisation dans le traitement de la dysmenorrhee et/ou des douleurs liees aux spasmes et crampes menstruels |
FR3122990B1 (fr) | 2021-05-20 | 2024-06-28 | Patrinove | Extrait de vegetal a metabolisme acide crassulacéen pour utilisation dans le traitement des dysfonctionnements érectiles |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3860710A (en) * | 1966-07-26 | 1975-01-14 | Consiglio Nazionale Ricerche | Method of inhibiting viral lysis in nonhuman flora and fauna systems |
DE1617409A1 (de) * | 1966-07-26 | 1971-04-01 | Consiglio Nazionale Ricerche | Praeparat zur Verhuetung,Hemmung und Inhibition der Lyse in lebenden Zellen fuer landwirtschaftliche und zootechnische Zwecke und Verfahren zur Herstellung des Praeparats |
JPS6185324A (ja) * | 1984-10-04 | 1986-04-30 | Satoshi Sasaki | 抗癌剤の製造法 |
JP3484638B2 (ja) * | 1993-03-18 | 2004-01-06 | 株式会社加美乃素本舗 | サボテン類植物抽出物含有皮膚化粧料 |
IL114848A0 (en) * | 1994-08-16 | 1995-12-08 | Chile Lab Sa | New composition and subcompositions of same process for obtaining them and their molecular identification and their anti-inflammatory analgesic antipruritic and local antipyretic therapeutic effect in human beings and animals |
-
1996
- 1996-12-27 FR FR9616116A patent/FR2757863B1/fr not_active Expired - Fee Related
-
1997
- 1997-12-22 WO PCT/FR1997/002375 patent/WO1998029128A1/fr active IP Right Grant
- 1997-12-22 PT PT97952968T patent/PT948340E/pt unknown
- 1997-12-22 JP JP52967998A patent/JP2001508424A/ja active Pending
- 1997-12-22 AP APAP/P/1999/001599A patent/AP1085A/en active
- 1997-12-22 ES ES97952968T patent/ES2174328T3/es not_active Expired - Lifetime
- 1997-12-22 AU AU56675/98A patent/AU726744B2/en not_active Ceased
- 1997-12-22 EP EP97952968A patent/EP0948340B1/fr not_active Expired - Lifetime
- 1997-12-22 DE DE69711230T patent/DE69711230T2/de not_active Expired - Fee Related
- 1997-12-22 DK DK97952968T patent/DK0948340T3/da active
- 1997-12-22 AT AT97952968T patent/ATE214612T1/de not_active IP Right Cessation
-
2002
- 2002-01-25 US US10/057,601 patent/US6737086B2/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10426723B2 (en) | 2014-12-03 | 2019-10-01 | Mary Kay Inc. | Cosmetic compositions |
US11103445B2 (en) | 2014-12-03 | 2021-08-31 | Mary Kay Inc. | Cosmetic compositions |
US11786453B2 (en) | 2014-12-03 | 2023-10-17 | Mary Kay Inc. | Cosmetic compositions |
Also Published As
Publication number | Publication date |
---|---|
EP0948340A1 (fr) | 1999-10-13 |
EP0948340B1 (fr) | 2002-03-20 |
DE69711230D1 (de) | 2002-04-25 |
WO1998029128A1 (fr) | 1998-07-09 |
DK0948340T3 (da) | 2002-07-01 |
FR2757863B1 (fr) | 1999-03-26 |
AP1085A (en) | 2002-07-29 |
FR2757863A1 (fr) | 1998-07-03 |
ES2174328T3 (es) | 2002-11-01 |
US6737086B2 (en) | 2004-05-18 |
AU726744B2 (en) | 2000-11-16 |
DE69711230T2 (de) | 2002-11-14 |
PT948340E (pt) | 2002-09-30 |
ATE214612T1 (de) | 2002-04-15 |
AU5667598A (en) | 1998-07-31 |
US20020102317A1 (en) | 2002-08-01 |
AP9901599A0 (en) | 1999-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001508424A (ja) | 生物学的に活性な物質と、その製造方法と、それを含む組成物 | |
US7026284B2 (en) | Formative agent of protein complex | |
JP2004519208A (ja) | 過酸化物で処理された酵母エキス及びその製造法 | |
EP0363491B1 (fr) | Preparation bacterienne pour prophylaxie et traitement de processus inflammatoires et d'affections allergiques | |
CN117625454A (zh) | 一株有抗糖化抗衰功能的副干酪乳酪杆菌ccfm1355及其后生元 | |
JPH04501256A (ja) | 増加する皮膚呼吸のための手段および方法 | |
Chayoth et al. | Increased cyclic AMP levels in malignant hepatic nodules of ethionine treated rats | |
HU208040B (en) | Composition containing biophysically modificated ascomyceta- or schizomyceta celles and process for poducing them | |
JPS61111693A (ja) | λP▲Lの下つき▼プロモ−タ−とリボソ−ム結合部位の置換に便利なように工学処理した制限部位とを含有する発現ベクタ−、このベクタ−を含有するプラスミド、このプラスミドを含有する宿主、および関連方法 | |
Kent et al. | Selective uptake of serum globulins and glycoproteins by cells growing in vitro | |
US20230039133A1 (en) | Composition for skin elasticity enhancement and wrinkle improvement comprising milk exosomes | |
KR100583792B1 (ko) | 황토수 및 생약재 추출물을 함유하는 피부미백, 항염증 및항비듬 화장료 조성물 | |
CN103933048A (zh) | 一种熊果酸衍生物在制备预防和治疗肿瘤转移药物中的应用 | |
JPH08176004A (ja) | 生体老化防止剤及び皮膚用組成物 | |
CA2079813A1 (en) | Method of treatment with hsp70 | |
Sahakyan et al. | INCREASING OF THE SUPEROXIDE DISMUTASE TOTAL ACTIVITY IN MICROGLIAL CELLS UNDER THE TREATMENT BY $ RIBES $$ NIGRUM $ L. ALCOHOL EXTRACT | |
CN108158960A (zh) | 具有缓解色素沉着作用的护唇口红 | |
JP2003321373A (ja) | 表皮細胞賦活剤、及びatp産生促進剤 | |
HU186767B (en) | Process for producing compositions for treating dermatologicalanomalys | |
FR3031040A1 (fr) | Procede d'obtention d'un extrait proteique concentre en superoxydase dismutase (sod) | |
KR20220125392A (ko) | 불소가 함유된 온천수 및 한방 복합 소재를 포함하는 다기능성 조성물 | |
JP4405611B2 (ja) | 肝障害防御剤 | |
CN103041369A (zh) | 藻蓝蛋白在制备防治有机磷农药所致雄性生殖毒性的药物中的应用 | |
CN104825574B (zh) | 一种改善睡眠的组合物及其制备方法 | |
Atici et al. | Protective effects of Berberis crataegina DC.(Ranunculales: Berberidaceae) extract on Bleomycin-induced toxicity in fruit flies (Diptera: Drosophilidae) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041019 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080729 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081029 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081208 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081127 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090109 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090317 |